News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Altimmune to Participate at Two Upcoming Conferences

Altimmune, Inc. (NASDAQ: ALT) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.

Altimmune Statement on the Passing of Dr. Stephen Harrison

Global COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023 [Yahoo! Finance]

3/27/2024

07:00 am

alt

1.9%

MISS

11/7/2023

07:00 am

alt

4.7%

BEAT

8/10/2023

07:00 am

alt

1.3%

BEAT

5/11/2023

07:00 am

alt

2.7%

BEAT

Form SC 13G/A Altimmune, Inc. Filed by: STATE STREET CORP

Form S-8 Altimmune, Inc.

Form 10-K Altimmune, Inc. For: Dec 31

Form 8-K Altimmune, Inc. For: Mar 27

Form SC 13G Altimmune, Inc. Filed by: MILLENNIUM MANAGEMENT LLC

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}